William E. Boden, MD, FACC, FAHA is Professor of Medicine and Preventive Medicine at the State University of New York at Buffalo Schools of Medicine and Public Health. He is Director of Cardiovascular Services at Kaleida Health System in Western New York and Chief of Cardiology at Buffalo General and Millard Fillmore Hospitals in Buffalo. He received his medical doctorate from State University of New York, Upstate Medical Center, Syracuse, NY, in 1974. Dr. Boden performed his internal medicine training at Boston University Medical Center (1974-1977) and went on to complete his fellowship training in cardiology at Tufts University School of Medicine in Boston, MA. He is board-certified in both internal medicine and in the subspecialty of cardiovascular diseases. Since 1979, Dr. Boden has held university appointments at Brown University, Wayne State University, Tufts New England Medical Center, Boston University, the University of Connecticut, and currently at the State University of New York in Buffalo.
Dr. Boden’s principal research interests include studies in post-myocardial infarction secondary prevention, acute coronary syndromes and unstable angina, congestive heart failure, and dyslipidemia in post-myocardial infarction (MI) and coronary artery disease (CAD). He has worked extensively in the clinical trials arena of non-Q-wave MI and in assessing the role of calcium antagonists in patients with ischemic heart disease, notably in non-Q-wave MI secondary prevention. Dr. Boden has been involved in clinical research investigator activities as the project director, study chairman, and co-chairman for multicenter clinical trials, and served as a principal investigator, steering committee member, and consultant for numerous clinical research grant activities funded by the Department of Veterans Affairs, the NIH, and industry. He was the study chairman and study co-chairman for the VANQWISH and INTERCEPT trials, respectively. Currently he is the study co-chairman and lead investigator in the COURAGE trial (the largest randomized trial comparison of percutaneous coronary intervention [PCI] vs optimal medical therapy in stable CAD patients), and is the study co-chairman of the NIH-funded AIM-HIGH trial evaluating the long-term role of combination dyslipidemic therapy (niacin and statin vs statin) in CAD patients with low HDL-cholesterol.
Dr. Boden has lectured widely and written more than 350 peer-reviewed publications, original articles, books, chapters, and abstracts. He has been selected as one of the Best Doctors in America continuously since 2003. He is a member of several professional cardiology organizations and editorial boards, including the American Journal of Cardiology, Journal of the American College of Cardiology, Clinical Cardiology, Journal of Cardiovascular Pharmacology and Therapeutics, and World Journal of Cardiology. Dr. Boden also serves as an editorial reviewer for New England Journal of Medicine, Annals of Internal Medicine, Circulation, Journal of the American Medical Association, American Heart Journal, and Archives of Internal Medicine.